• Comments


Private Placement Offering Event Set for June 27th at Lone Star Park

DENVER, Colorado -- June 13, 2014 - Willowcroft Pharm, Inc., developer of the successful laminitis drug treatment, Laminil, announced today that it is offering up to 60,000,000 shares of preferred stock at a price of $0.08333 per share. Willowcroft Pharm intends to use the net proceeds for securing FDA approval and commercialization of Laminil. The closing date of the offering is expected to be August 1st. The offering event is scheduled for Friday, June 27th at 8:30 PM.

The company noted that the injectable drug is being successfully tested around the world at major veterinary clinics. In over one year of Laminil use, one clinic stated, "We have not had to euthanize a single laminitis horse since using Laminil."

Please visit to learn more about this opportunity to invest at the ground floor and be a part of the solution to a centuries old fatal disease.

First Post the day of the event is set for 6:35 PM.

About Laminil:

Laminil is an injectable drug developed to halt the inflammatory response and laminitis cascade of acute laminitis and active chronic laminitis. Laminitis is a crippling and often fatal disease, characterized by inflammation of the tissues that connect the hoof wall to the coffin bone in a horse's foot. Laminil is an investigational drug going through the FDA approval process. Laminil has shown promise with all types of laminitis, such as insulin resistance, equine metabolic syndrome, grain overload, grass founder, trauma and single limb laminitis.

About Willowcroft Pharm, Inc.:

Willowcroft Pharm, Inc., is a privately held pharmaceutical company engaged in saving horses and other animals, from the debilitating, painful and life-threatening disease laminitis. For more information about Willowcroft Pharm, Inc., and the Laminil development program, please visit

The shares offered in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws, and may not be offered or sold in the United States without being registered with the Securities and Exchange Commission (SEC) or through an applicable exemption from SEC registration requirements. The shares of preferred stock are offered only to accredited investors.

Safe Harbor Statement
: This press release contains forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the likelihood and potential benefit to the Company's stockholders of the Company entering into a strategic transaction, the adequacy of the Company's capital to support the Company's operations, the potential of the Company's Laminil market authorization. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Recent Posts


Disclaimer: The statements/claims expressed herein are solely the views or opinions of the person(s)/company submitting the information to Blood-Horse Publications and do not necessarily reflect the views or opinions of Blood-Horse Publications, nor have these statements/products/services been reviewed/evaluated by Blood-Horse Publications prior to publication. Any claims/statements made herein should not be attributed to Blood-Horse Publications.

More Blogs